As Taiwan’s leading researcher and manufacturer of microarray patches (MAPs), we were honored to be invited as a featured speaker at StartUp@Taipei, held in Osaka, Japan, from August 18 to 22.
It was an inspiring opportunity to showcase our innovations in MAPs—particularly our latest healthcare MAPs and our flagship pipeline product, the diclofenac sodium MAP—to partners, peers, and industry leaders in Japan. With Japan’s rapidly aging society, transdermal dosage forms have become one of the best-selling drug delivery solutions in the country. This trend stems from the limitations of oral administration, such as difficulty swallowing and gastrointestinal side effects.
Our novel precision microneedle technology offers a superior alternative by combining the convenience of transdermal delivery with faster onset and sustained therapeutic effects. Unlike conventional patches, our MAPs ensure efficient drug absorption with minimal discomfort, positioning them as the next-generation solution to meet Japan’s growing healthcare and pharmaceutical needs.
Through this event, we gained invaluable connections that will help accelerate our MAPs into the Japanese market, supported by enhanced regulatory insights, strategic partnerships, and additional funding opportunities as we prepare for our IPO in 2027.
Click on the following articles for further reading: Article 1 | Article 2